Determination of the investment project cost in developing a new generic medicine based on the content approach
DOI:
https://doi.org/10.24959/sphhcj.19.139Keywords:
cost of development, structure of investments, registration dossier, marketing approach, economic approach, investment project, development, medicinesAbstract
Aim. To determine the approximate cost of an investment project in developing a new medicine based on the generic type in the form of tablets taking into account the content approach in the common technical document (CTD) format of the registration dossier.
Materials and methods. As materials the reports on research work in developing drugs, scientific publications, the own research and monitoring results of the pharmaceutical market of pharmaceutical company “Farmstandart” were used. The methods of generalization, systematization of the theoretical and practical material, marketing analysis, comparative and economic methods were applied.
Results. The analysis and generalization of materials in determining the cost of development of new drugs has been conducted. On the example of the generic type medicine in the form of tablets in accordance with the requirements of the normative documents to the formation of the registration dossier in the CTD format the cost of the drug development and the necessary investments for each of five modules has been processed.
Conclusions. The importance and necessity of determining the cost of developing a new drug as a complex product project have been substantiated. On the example of the generic type medicine in the form of tablets taking into account the requirements of normative documents the definition of the cost of development by 5 modules of the registration dossier has been worked out.
References
Light, D. (2011). Demythologizing the high costs of pharmaceutical research. Bio Societies, 6. 34–50.
Khonl, T. A. (2013). Problemy ucheta i finansov, 2 (10), 52–54.
Posylkina, O. V. (2003). Visnyk farmatsii, 2 (34), 68–72.
Nemchenko, A. S., Nazarkina, V. M. (2015). Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 3 (41), 38–43.
Baigush, Yu. V., Slobodianiuk, M. M., Samborskyi, O. S. (2016). Proceeding from Upravlinnia yakistiu v farmatsii: zbirnyk naukovykh robit X naukovo–praktychnoi konferentsii z mizhnarodnoiu uchastiu (20 travnya 2016) (pp. 18–20). Kharkiv.
Demkyn, Y. V., Streltszov, A. V., Haletov, Y. D. (2004). Upravlenie riskom, 4, 16–27.
Kovalenko, Sv. M. (2015). Visnyk farmatsii, 4 (84), 47–51.
Malyi, V. V. Musa Istanis Marvek Medkhat. (2018) Sotsialna farmatsiia v okhoroni zdorovia, 3(4), 59–68. doi: 10.24959/sphhcj.17.82.
Usherenko, S. V., Chernenko, D. D. (2015). Chasopys ekonomichnykh reform, 2 (18), 92–98.
Slobodianiuk, M. M., Samborskyi, O. S. (2018). Proceeding from Sotsialna farmatsiia: stan, problemy ta perspektyvy: materialy IV mizhnarodnoi naukovo–praktychnoi internet–konferentsyi (24 – 25 kvitnia 2018) (pp. 168–171). Kharkiv.
Hrebenyk, K. Likuvalni investytsii: u shcho vkladaty hroshi v ukrainskii farmi. Available at : https://mind.ua/publications/20184249–likuvalni–investiciyi–u–shcho–vkladati–groshi–v–ukrayinskij–farmi
Kotvitska, A. A. (2008). Visnyk farmatsii, 1, 56–59.
Slobodianiuk, M. M., Zhadko, S. V. (2008). Otsinka pryvablyvosti segmentu rynku likarskykh preparativ pry formuvanni tovarnoho asortymentu farmatsevtychnogo pidpryemstva. Kharkiv, 28.
Samborskyi, O. S., Slobodianiuk, M. M. (2017). Proceeding from Relevant issues of modern medicine: the experience of Poland and Ukraine: International research and practice conference (20–21 October 2017) (pp.127–129). Lublin.
Iliashenko, S. N. (2013). Nauchnue osnovu marketynha ynnovatsyi. Sumy, 284.
Barratt, Michael J., Frail, Donald E. (Eds). (2012). Drug repositioning: bringing new life to shelved assets and existing drugs / edited by Frail, Wiley, 470.
Winegarden, W. (2014). The Economics of Pharmaceutical pricing. San Francisco, 27.
Skolko segodnya stoit razrabotka novogo preparata? (2012). Ezhened. “Apteka”. Available at: https://www.apteka.ua/article/133253
Slobodianiuk, M. M., Samborskyi, O. S. (2017). Teoretychni osnovy ta metodyka obgruntuvannya efektyvnosti j investycijnoyi pryvably`vosti rozrobok ta vprovadzhennya likarskyx zasobiv na osnovi proektnogo planuvannya ta kompyuternoyi obrobky. Kyyiv, 36.
Slobodianiuk, M. M., Samborskyi, O. S., Hermanovski, T. (2017). Sotsialna farmatsiia v okhoroni zdorovia, 3 (4), 19–31. doi: 10.24959/sphhcj.17.95.
Slobodianiuk, M. M., Samborskyi, O. S., Hermanovski, T. (2017). Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 4 (52), 50–58. doi: 10.24959/uekj.17.32.
Nakaz Derzhavnogo farmakologichnogo centru MOZ Ukrainy vid 20.08.2010 roku No. 97 “Pro zatverdzhennia roztsinok vartosti poslug, shho nadaiutsia DP “Derzhavnyi farmakologichnyi centr» MOZ Ukrainy”. (2010). zakon.rada.gov.ua. Available at: https://zakon.rada.gov.ua/rada/show/v0097613-10
Nakaz MOZ Ukrainy vid 26.08.2005 No. 426 “Pro zatverdzhennia Poriadku provedennia ekspertyzy reiestratsiinykh materialiv na likarski zasoby, shcho podaiutsia na derzhavnu reiestratsiiu (perereiestratsiiu), a takozh ekspertyzy materialiv pro vnesennia zmin do reiestratsiinykh materialiv protiahom dii reiestratsiinoho posvidchennia”. (2005). zakon.rada.gov.ua. Available at: https://zakon.rada.gov.ua/laws/show/z1069–05#n21
DiMasi, J. A., Hansen, R. W., Grabowski, H. G., Lasagna, L. (1991). Cost of innovation in the pharmaceutical industry. Journal of Health Economics, 10 (2), 107–142.
Ding, M., Eliashberg, J., Stremersch, St. (2014). Marketing in the Pharmaceutical Industry. Chapter 3. Portfolio Management in New Drug Development. New York, 83–117.
DiMasi, J. A., Hansen, R. W., Grabowski, H. G. (2003). The price of innovation: new estimates of drug development costs. Journal of Health Economics, 22 (3), 141–185.
Downloads
Published
Issue
Section
License
Copyright (c) 2019 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
